BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23016269)

  • 1. [Statistical analysis of 32 patients with nasopharyngeal carcinoma].
    Fujii R; Imanishi Y; Tomita T; Sakamoto K; Shigetomi S; Habu N; Ootsuka K; Sato Y; Ozawa H; Yamashita T; Fujii M; Shigematsu N; Ogawa K
    Nihon Jibiinkoka Gakkai Kaiho; 2012 Aug; 115(8):773-82. PubMed ID: 23016269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
    Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
    Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
    Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
    Zhou J; Zhang WM; Chen H; Xie B; Zheng JH; Xu ZY; Lin JR
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):867-72. PubMed ID: 20137355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognoses and long-term outcomes of nasopharyngeal carcinoma in Han and Uyghur patients treated with intensity-modulated radiotherapy in the Xinjiang Autonomous Region of China.
    Wang R; Tan Y; Wang X; Ma L; Wang D; Hu Y; Qin Y; Liu K; Chang C; Yu J
    PLoS One; 2014; 9(11):e111145. PubMed ID: 25375129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
    Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
    Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.
    Yu Y; Liang H; Lv X; Ke L; Qiu W; Huang X; Liu G; Li W; Guo X; Xiang Y; Xia W
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2231-2243. PubMed ID: 30109501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?
    Lin JC; Liang WM; Jan JS; Jiang RS; Lin AC
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):156-64. PubMed ID: 15337551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.